Galenica's kidney drug meets endpoint in trial
Home page > News

Galenica's kidney drug meets endpoint in trial

www.reuters.com   | 09.07.2012.

ZURICH (Reuters) - Swiss healthcare company Galenica said on Monday that its kidney drug PA21 successfully met primary and secondary endpoints in a late-stage trial, paving the way for regulatory filings in the United States, Europe and Switzerland.
br />

Results of the six-month phase III study found that maintenance doses of PA21 were superior in sustaining the phosphate-lowering effect in patients with chronic kidney disease who are on dialysis versus a PA21 inactive low dose.

The company plans to submit PA21, which it developed in collaboration with Fresenius Medical Care, for regulatory approval in the fourth-quarter of 2012.

(Reporting by Caroline Copley)


Comments (0) Add Your comment Add news < Previous news Next news >






  Add your news >>>